Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Janssen Research & Development, LLC clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
703
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Janssen Research & Development, LLC
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Janssen Research & Development, LLC. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 397–408 of 703 matching trials for sponsor Janssen Research & Development, LLC.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir

NCT02961660
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Odalasvir
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional

Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer

NCT02625857
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
JNJ-64041809 (Cohort 1A and 1B), JNJ-64041809 (Cohort 2A and 2B)
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants

NCT02674295
View directory record Official record
Conditions
Healthy
Interventions
Esketamine 50 mg, Esketamine 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

NCT03320707
View directory record Official record
Conditions
Healthy
Interventions
Daratumumab, Placebo, rHuPH20
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

NCT04147338
View directory record Official record
Conditions
Healthy
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects

NCT02857777
View directory record Official record
Conditions
Healthy
Interventions
Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

NCT03864601
View directory record Official record
Conditions
Healthy
Interventions
14C-JNJ-56136379
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

NCT02475161
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Rabeprazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

NCT03952507
View directory record Official record
Conditions
Healthy
Interventions
JNJ-64417184 600 (Oral Tablet Formulation), JNJ-64417184 (Oral Suspension Formulation)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

NCT04667052
View directory record Official record
Conditions
Healthy
Interventions
JNJ 64304500
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Phase 1 Interventional

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

NCT03298542
View directory record Official record
Conditions
Pre-Symptomatic Type 1 Diabetes
Interventions
Golimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 4, 2026, 5:48 AM EST
Completed Early Phase 1 Interventional

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

NCT03473730
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
Interventions
Biopsy, Daratumumab, Laboratory Biomarker Analysis, Metastasectomy, Nephrectomy
Procedure · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Nov 4, 2026, 5:48 AM EST

About this Janssen Research & Development, LLC sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Janssen Research & Development, LLC is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Janssen Research & Development, LLC trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Janssen Research & Development, LLC.